CAMBRIDGE, Mass.--(BUSINESS WIRE)--HyperLight, creator of the TFLN Chipletâ„¢ platform, today announced the launch of its groundbreaking 110 GHz Low VÏ€ Intensity Modulator, featuring industry-standard ...
Of the 300 patients in the PARCER trial, 93 faced grades ≥2 adverse events (3D-CRT = 59, IG-IMRT = 34). Patients in the 3D-CRT and IG-IMRT arms spent an average of 2.39 years and 1.96 years in ...
Role of induction chemotherapy with docetaxel+cisplatin+5-FU (DCF) followed by radiotherapy for patients with inoperable head and neck cancer to observe local control Target delineation, area coverage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results